Organ Programs
Miromatrix is developing bioengineered organs for transplantation and other life saving applications. Our technology can be applied across the spectrum of donor needs. We are currently focused on bioengineering transplantable kidneys (mirokidney®), livers (miroliver®), and a bioengineered external liver assist device for acute liver failure (miroliverELAP®), with plans to also bioengineer other critical organs like lungs, pancreases and hearts.
Acute liver failure (ALF) is a devastating condition that affects thousands of patients each year and the only effective treatment is liver transplantation. Unfortunately, given the lack of shortage of transplantable livers and the rapid onset of ALF, approximately 30% of patients die without access to a liver transplant. 1
Miromatrix is developing a new liver therapy called miroliverELAP®. The miroliverELAP® system combines a Miromatrix single-use bioengineered liver with an extra corporeal blood circuit. Miromatrix received IND clearance for miroliverELAP® and will initiate a clinical trial in 2024.
Miromatrix’s miroliverELAP® bioengineered liver is designed to replicate key functions of a human liver and is connected outside of the patient’s body to create the miroliverELAP® system. The system is designed to provide external liver support to ALF patients.
End-stage renal disease (ESRD), which is the final stage of chronic kidney disease and 9th leading cause of death in the United States, affects an estimated 100,000 people each year in the U.S.
These patients join the over 550,000 patients in America that either require chronic dialysis or dialysis while waiting for a kidney transplant. In 2018, there were more than 100,000 patients on the kidney transplant waitlist in the U.S. but only ~25,000 received a transplant . The only curative therapy for ESRD is a kidney transplant, yet the shortage of donor kidneys means many patients languish on the transplant waitlist for years while undergoing expensive and time-consuming dialysis treatment.
Miromatrix is bioengineering transplantable kidneys based on our patented perfusion decellularization and recellularization technology with the goal of developing new options for patients who need a kidney transplant.
It is estimated that 30 million people in the U.S. have some type of liver disease, and 5.5 million Americans have chronic liver disease or cirrhosis.
Chronic liver disease can be managed with medications and lifestyle changes if it has not progressed to end-stage liver disease (ESLD). Once it progresses to ESLD, a liver transplant is typically the best treatment option. Similar to all end-stage organ failures, a shortage of available organs is one of the largest challenges facing patients in need of a transplant.
Miromatrix is bioengineering transplantable livers based on our patented perfusion decellularization and recellularization technology with the goal of developing new options for patients in need of a liver transplant.
In our state-of-the-art facilities, we are utilizing clinical-sized implants and have achieved major preclinical milestones: successfully revascularizing a decellularized porcine liver graft with human vascular cells and demonstrated sustained perfusion for 15 days post-transplantation and recellularizing with hepatocytes and human vascular cells demonstrating key liver function both before and after transplantation in a large animal model.
1 William M. Lee, Robert H. Squires Jr, Scott L. Nyberg, Edward Doo, and Jay H. Hoofnagle (2008 April). Acute liver failure: Summary of a workshop (PDF). Hepatology, 47(4), 1401–1405. Back to content